

Stable analogues of the dual agonist dogfish glucagon show better therapeutic potential than exendin-4 in diet induced obese diabetic mice

Finbarr P.M. O'Harte, Ming T. Ng, J. Michael Conlon & Peter R. Flatt

Ulster University


Saad Centre for Pharmacy & Diabetes, School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, Northern Ireland

BACKGROUND


- In addition to promoting hepatic glucose output, glucagon has potential in mobilization of fat stores.
 - Incretin hormones such as GLP-1 have potent glucose lowering and appetite suppressing activities.
 - Novel dual agonist peptides which stimulate both incretin and glucagon receptors have potential in the treatment of Type 2 diabetes
 - Dogfish glucagon shares about 50% structural homology with GLP-1 and GIP(1-30).
- AIM:** To test the efficacy of stable dogfish glucagon related analogues Pep N and Pep C, versus exendin-4 treatment in combatting diet induced obesity diabetes in high fat fed mice.

METHODS

Experimental design




Primary structure of dogfish glucagon and D-A² analogues




RESULTS


Effect of chronic treatment with Pep N, Pep C and exendin-4 on (A) body weight and (B) body weight change in high fat fed mice



Effect of chronic treatment with Pep N, Pep C and exendin-4 on (A) cumulative food intake and (B) body weight change in high fat fed mice




Effect of chronic treatment with Pep N, Pep C and exendin-4 on non-fasting blood glucose (A) and plasma insulin (B) in high-fat fed mice




Peptide	Primary sequence
Dogfish glucagon	HSEGT FTSDY SKYMD NRRAK DVFQW LMNT
Human glucagon	HSQGT FTSDY SKYLD SRRRAQ DVFQW LMNT
GLP-1(7-36)amide	HAEGT FTSDV SSYLE GQAAK EFLAW LVKGR-amide
GIP(1-30)	YAEGT FSDY SIAMD KIHQQ DFNW LLAQK

RESULTS


Effect of chronic treatment with Pep N, Pep C and exendin-4 on blood glucose (A) and plasma insulin (B) in response to an ipGTT in high-fat diet fed mice



Effect of chronic treatment with Pep N, Pep C and exendin-4 on insulin sensitivity in high-fat diet fed mice



Effect of chronic treatment with Pep N, Pep C and exendin-4 on (A) % fat mass as measured by DEXA scan and (B) plasma triglycerides in high-fat diet fed mice



Blood glucose and insulin concentrations were measured prior to and after i.p. glucose challenge (18 mmol/kg body weight) in fasted mice. Values represent mean ± SEM for 8 mice. *p<0.05, **p<0.01 and ***p<0.001 compared with saline-treated group.


Insulin (25 U/kg bw) was administered by i.p. injection at t=0 min. Values represent mean ± SEM for 8 mice. *p<0.05, **p<0.01 and ***p<0.001 compared with saline-treated group.

Values are mean ± SEM for n=8. *p<0.05, **p<0.01 and ***p<0.001 compared with saline-treated control group.

RESULTS

Conclusion

Effect of chronic treatment with Pep N, Pep C and exendin-4 on (A) pancreatic insulin content and (B) plasma glucagon



Summary

Chronic (D-A²)dogfish glucagon (Pep N) and (D-A²)dogfish glucagon exendin (Pep C) administration:

- along with exendin-4 caused a reduction in body weight gain (Fig. 1B) in high fat diet fed (HFD) mice.
- had no significant effect on cumulative food intake in HFD mice (Fig. 2)
- along with exendin-4 significantly decreased non-fasting blood glucose and stimulated plasma insulin by day 3 and this was sustained throughout the study (Fig. 3)
- along with exendin-4 significantly improved glucose tolerance and insulintropic activities in response to ipGTT in HFD mice (Fig. 4)
- Exendin-4 and Pep C improved tissue insulin sensitivity in HFD mice (Fig. 5)
- reduced the % body fat mass and circulating glucagon concentrations in HFD mice (Fig. 6) and were more effective than exendin-4
- Exendin-4 and Pep C reduced plasma triglyceride concentrations in HFD mice
- along with exendin-4 had no effect upon pancreatic insulin content in HFD mice

- These studies demonstrate the efficacy of (D-A²)dogfish glucagon and (D-A²)dogfish glucagon exendin, which share structural homology with incretin hormones, in combatting chronic glucose induced hyperglycaemia and dyslipidaemia in diet induced obese diabetic mice.

Acknowledgements:

This work was supported by Invest NI Proof of Concept (POC308) funding and by a DEL PhD Studentship award.

